{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:48:46Z","timestamp":1761162526019,"version":"build-2065373602"},"reference-count":15,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T00:00:00Z","timestamp":1326672000000},"content-version":"vor","delay-in-days":3243,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2003,3]]},"abstract":"<jats:p>\n                    Several commercially available weight\u2010loss supplements contain ma\u2010huang, an herb derived from\n                    <jats:italic>Ephedra sinica.<\/jats:italic>\n                    Previous reports have raised awareness that ma\u2010huang supplements may precipitate symptoms consistent with mania in susceptible individuals. A 21\u2010year\u2010old woman required psychiatric hospitalization as a result of acute manic symptoms with psychosis. The emergence of her symptoms coincided with her use of two supplements containing ma\u2010huang. Consumers need to be educated about the potential adverse psychiatric effects of ma\u2010huang in order to make well\u2010informed decisions before using such supplements. A preexisting psychiatric disorder may also increase susceptibility to these adverse effects.\n                  <\/jats:p>","DOI":"10.1592\/phco.23.3.380.32114","type":"journal-article","created":{"date-parts":[[2004,5,11]],"date-time":"2004-05-11T07:27:08Z","timestamp":1084260428000},"page":"380-383","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Possible Case of Mania Associated with Ma\u2010Huang"],"prefix":"10.1002","volume":"23","author":[{"given":"Joel M.","family":"Boerth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles F.","family":"Caley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,16]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"746","article-title":"Hypomania and St. John's wort","volume":"43","author":"O'Breasail AM","year":"1998","journal-title":"Can J Psychiatry"},{"doi-asserted-by":"publisher","key":"e_1_2_1_3_2","DOI":"10.1097\/00004714-200002000-00027"},{"doi-asserted-by":"publisher","key":"e_1_2_1_4_2","DOI":"10.1016\/S0006-3223(99)00233-4"},{"doi-asserted-by":"publisher","key":"e_1_2_1_5_2","DOI":"10.1097\/00004714-199512000-00014"},{"doi-asserted-by":"publisher","key":"e_1_2_1_6_2","DOI":"10.1016\/S0033-3182(00)71174-1"},{"doi-asserted-by":"publisher","key":"e_1_2_1_7_2","DOI":"10.1176\/ajp.152.4.647a"},{"doi-asserted-by":"publisher","key":"e_1_2_1_8_2","DOI":"10.1176\/ajp.155.11.1626b"},{"doi-asserted-by":"publisher","key":"e_1_2_1_9_2","DOI":"10.1176\/appi.ajp.159.2.318-a"},{"doi-asserted-by":"publisher","key":"e_1_2_1_10_2","DOI":"10.1038\/sj.ijo.0801539"},{"doi-asserted-by":"publisher","key":"e_1_2_1_11_2","DOI":"10.4088\/JCP.v59n0207d"},{"doi-asserted-by":"publisher","key":"e_1_2_1_12_2","DOI":"10.1176\/ajp.154.5.711a"},{"doi-asserted-by":"publisher","key":"e_1_2_1_13_2","DOI":"10.1056\/NEJM200012213432502"},{"unstructured":"Food and Drug Administration.Dietary supplements containing ephedrine alkaloids.June 4 1997. Available fromwww.cfsan.fda.gov~lrdfr97064a.html. Accessed October 28 2002.","key":"e_1_2_1_14_2"},{"issue":"10","key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/ajhp\/57.10.963","article-title":"Content versus label claims in ephedra\u2010containing dietary supplements","volume":"57","author":"Gurley BJ","year":"2000","journal-title":"Am J Health-Syst Pharm"},{"doi-asserted-by":"publisher","key":"e_1_2_1_16_2","DOI":"10.1038\/clpt.1981.154"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.23.3.380.32114","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.23.3.380.32114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:00:20Z","timestamp":1761066020000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.23.3.380.32114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["10.1592\/phco.23.3.380.32114"],"URL":"https:\/\/doi.org\/10.1592\/phco.23.3.380.32114","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2003,3]]},"assertion":[{"value":"2012-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}